Kingswood Wealth Advisors LLC Reduces Stock Position in Johnson & Johnson $JNJ

Key Points

• Kingswood Wealth Advisors LLC significantly reduced its stock holdings in Johnson & Johnson by 57.5% during the second quarter, now owning 12,760 shares valued at approximately $1.95 million.
• Johnson & Johnson recently reported a quarterly EPS of $2.77, exceeding analysts' expectations, with revenue totaling $23.74 billion, up 5.8% year-over-year.
• The company announced a quarterly dividend of $1.30 per share, translating to an annualized dividend yield of 2.7%.

Kingswood Wealth Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 57.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,760 shares of the company's stock after selling 17,277 shares during the period. Kingswood Wealth Advisors LLC's holdings in Johnson & Johnson were worth $1,949,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Highline Wealth Partners LLC boosted its stake in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth about $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the 1st quarter worth about $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.5%

NYSE:JNJ opened at $189.75 on Thursday. Johnson & Johnson has a one year low of $140.68 and a one year high of $190.22. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $456.98 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40. The firm has a 50-day simple moving average of $177.49 and a 200-day simple moving average of $163.37.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analyst Ratings Changes

Several research firms have issued reports on JNJ. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Weiss Ratings raised shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $189.88.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.